UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy

The New England journal of medicine, 2008-06, Vol.358 (23), p.2433-2446

2008

Volltextzugriff (PDF)

Renin inhibition with aliskiren : where are we now, and where are we going?

Journal of hypertension, 2006-02, Vol.24 (2), p.243-256

2006

Volltextzugriff (PDF)

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus

Journal of hypertension, 2007-09, Vol.25 (9), p.1921-1926

2007

Volltextzugriff (PDF)

Renin Inhibition: What Are the Clinical Perspectives?

Seminars in nephrology, 2007-09, Vol.27 (5), p.511-518

Hollenberg, Norman K., MD, PhD

2007

Volltextzugriff (PDF)

Recommendations for Evaluating Compliance and Persistence With Hypertension Therapy Using Retrospective Data

Hypertension (Dallas, Tex. 1979), 2006-06, Vol.47 (6), p.1039-1048

2006

Volltextzugriff (PDF)

Influencing the natural history of hypertension: is it the blood pressure achieved, the drug, or the drug dose?

Journal of hypertension, 2008-08, Vol.26 (8), p.1527-1532

Hollenberg, Norman K

2008

Volltextzugriff (PDF)

The Role of β-Blockers as a Cornerstone of Cardiovascular Therapy

American journal of hypertension, 2005-12, Vol.18 (12), p.165S-168S

Hollenberg, Norman K.

2005

Volltextzugriff (PDF)

Antihypertensive effects of double the maximum dose of valsartan in African–American patients with type 2 diabetes mellitus and albuminuria

Journal of hypertension, 2010-01, Vol.28 (1), p.186-193

2010

Volltextzugriff (PDF)

Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin–angiotensin–aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients

Journal of hypertension, 2011-10, Vol.29 (10), p.2031-2037

2011

Volltextzugriff (PDF)

A brief response to Sealey and Laragh

Journal of the renin-angiotensin-aldosterone system, 2007-06, Vol.8 (2), p.53-53

Hollenberg, Norman K

2007

Volltextzugriff (PDF)

The renin system: is direct renin inhibition different from blockade at the AT1 receptor or the ACE step?

Reviews in cardiovascular medicine, 2007, Vol.8 Suppl 2, p.S7-13

Hollenberg, Norman K

2007

Volltextzugriff (PDF)

Renal implications of angiotensin receptor blockers

American journal of hypertension, 2001-08, Vol.14 (7), p.237S-241S

Hollenberg, Norman K

2001

Volltextzugriff (PDF)

Angiotensinogen genotype affects renal and adrenal responses to angiotensin II in essential hypertension

Circulation (New York, N.Y.), 2002-04, Vol.105 (16), p.1921-1927

2002

Volltextzugriff (PDF)

Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics

American journal of hypertension, 2004-07, Vol.17 (7), p.638-640

2004

Volltextzugriff (PDF)

Hypertension, small arteries, and pathways for angiotensin II generation: "The proper study of mankind is man"

Circulation (New York, N.Y.), 2000-04, Vol.101 (14), p.1641-1642

Hollenberg, N K

2000

Volltextzugriff (PDF)

Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure

Current hypertension reports, 2001, Vol.3 Suppl 1 (1), p.S25-S28

Hollenberg, N K

2001

Volltextzugriff (PDF)

Short- and long-term glycaemic control and the state of the renin system in type 1 diabetes mellitus

Journal of the renin-angiotensin-aldosterone system, 2007-06, Vol.8 (2), p.85-92

2007

Volltextzugriff (PDF)

Treatment of the patient with diabetes mellitus and risk of nephropathy: what do we know, and what do we need to learn?

Archives of internal medicine (1960), 2004-01, Vol.164 (2), p.125

Hollenberg, Norman K

2004

Volltextzugriff (PDF)

Diuretic-induced potassium and magnesium deficiency: relation to drug-induced QT prolongation, cardiac arrhythmias and sudden death

Journal of hypertension, 1992-04, Vol.10 (4), p.301-316

1992

Volltextzugriff (PDF)

Evolution of the treatment of hypertension: What really matters in the 1990s?

The American journal of medicine, 1992-08, Vol.93 (2), p.S4-S10

Hollenberg, Norman K.

1992

Volltextzugriff (PDF)

Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension

Archives of internal medicine (1960), 2003-07, Vol.163 (13), p.1543

2003

Volltextzugriff (PDF)

Accentuated vascular and endocrine response to SQ 20881 in hypertension

The New England journal of medicine, 1977-07, Vol.297 (4), p.184-188

1977

Volltextzugriff (PDF)

Omission of drug dose information

Archives of internal medicine (1960), 2006-02, Vol.166 (3), p.368; author reply 368

Hollenberg, Norman K

2006

Volltextzugriff (PDF)

Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life

Archives of internal medicine (1960), 1999-04, Vol.159 (7), p.693

1999

Volltextzugriff (PDF)

Contribution of Prostaglandins to the Antihypertensive Action of Captopril in Essential Hypertension

Hypertension (Dallas, Tex. 1979), 1981-03, Vol.3 (2), p.168-173

1981

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Aktive Filter

ThemaHypertension - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(63)

Sprache

Englisch
(63)

Erscheinungsjahr

n.n

Thema

Humans
(62)
Life Sciences & Biomedicine
(54)
Science & Technology
(54)
Space Life Sciences
(39)
Cardiovascular System & Cardiology
(33)
Peripheral Vascular Disease
(27)
Biological And Medical Sciences
(23)
Medical Sciences
(23)
Antihypertensive Agents - Therapeutic Use
(22)
Male
(22)
Female
(20)
Hypertension - Physiopathology
(20)
Middle Aged
(20)
Adult
(17)
General & Internal Medicine
(16)
Medicine, General & Internal
(16)
Renin-Angiotensin System - Drug Effects
(16)
Pharmacology. Drug Treatments
(15)
Aged
(14)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy

Renin inhibition with aliskiren : where are we now, and where are we going?

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus

Renin Inhibition: What Are the Clinical Perspectives?

Recommendations for Evaluating Compliance and Persistence With Hypertension Therapy Using Retrospective Data

Influencing the natural history of hypertension: is it the blood pressure achieved, the drug, or the drug dose?

The Role of β-Blockers as a Cornerstone of Cardiovascular Therapy

Antihypertensive effects of double the maximum dose of valsartan in African–American patients with type 2 diabetes mellitus and albuminuria

Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin–angiotensin–aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients

A brief response to Sealey and Laragh

The renin system: is direct renin inhibition different from blockade at the AT1 receptor or the ACE step?

Renal implications of angiotensin receptor blockers

Angiotensinogen genotype affects renal and adrenal responses to angiotensin II in essential hypertension

Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics

Hypertension, small arteries, and pathways for angiotensin II generation: "The proper study of mankind is man"

Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure

Short- and long-term glycaemic control and the state of the renin system in type 1 diabetes mellitus

Treatment of the patient with diabetes mellitus and risk of nephropathy: what do we know, and what do we need to learn?

Diuretic-induced potassium and magnesium deficiency: relation to drug-induced QT prolongation, cardiac arrhythmias and sudden death

Evolution of the treatment of hypertension: What really matters in the 1990s?

Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension

Accentuated vascular and endocrine response to SQ 20881 in hypertension

Omission of drug dose information

Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life

Contribution of Prostaglandins to the Antihypertensive Action of Captopril in Essential Hypertension

Aktive Filter

Suchergebnisse filtern